Itraconazole Dosing Recommendations
For onychomycosis, itraconazole should be dosed at 200 mg daily for 12 weeks continuously OR as pulse therapy at 400 mg daily for 1 week per month (2 pulses for fingernails, 3 pulses for toenails), though terbinafine remains superior and should be first-line when treating dermatophyte infections. 1
Onychomycosis (Nail Infections)
Licensed Dosing Regimens
- Continuous therapy: 200 mg daily for 12 weeks 1
- Pulse therapy: 400 mg daily for 1 week per month
- Fingernails: 2 pulses (2 months total)
- Toenails: 3 pulses (3 months total) 1
Important Caveats
While both regimens are licensed, terbinafine demonstrates superior efficacy for dermatophyte onychomycosis. A large multicenter trial showed complete cure rates of 55% with terbinafine versus only 26% with pulsed itraconazole at 72 weeks, with significantly higher relapse rates in the itraconazole group (53% vs 23%) 1. Reserve itraconazole for patients who cannot tolerate terbinafine or when treating Candida/non-dermatophyte mold infections where itraconazole has broader spectrum coverage 1.
Candida Onychomycosis
Itraconazole is first-line for Candida nail infections due to superior efficacy over terbinafine and shorter treatment duration 1:
- 200 mg daily OR 400 mg daily pulse therapy (1 week/month)
- Minimum duration: 4 weeks for fingernails, 12 weeks for toenails 1
Endemic Mycoses (Paracoccidioidomycosis)
For mild-to-moderate paracoccidioidomycosis, use 200 mg daily for 9-12 months, which shows 91% efficacy and is superior to co-trimoxazole 2. For severe cases, initiate with amphotericin B for 2-4 weeks, then follow with 200-400 mg itraconazole 2.
Pediatric Dosing
Onychomycosis in Children
Pulse therapy: 5 mg/kg/day for 1 week per month 1
- Fingernails: 2 pulses
- Toenails: 3 pulses
Alternative for children unable to swallow capsules: Oral solution at 3 mg/kg/day as pulse therapy (1 week on, 3 weeks off, for 2 cycles) 3
Systemic Fungal Infections in Infants
Pediatric studies show higher cure rates (94-100%) and faster response compared to adults, with good tolerability 1.
Oropharyngeal and Esophageal Candidiasis
Per FDA labeling 5:
- Oropharyngeal candidiasis: 200 mg (20 mL oral solution) daily for 1-2 weeks
- Swish vigorously in mouth before swallowing
- For fluconazole-refractory cases: 100 mg twice daily
- Esophageal candidiasis: 100 mg daily for minimum 3 weeks, continue 2 weeks after symptom resolution
- May increase to 200 mg daily based on response
Critical point: Oral solution and capsules are NOT interchangeable. Only oral solution is effective for oral/esophageal candidiasis 5.
Key Safety Considerations
Drug Interactions
Itraconazole is a potent CYP3A4 inhibitor with extensive drug interactions 5. Avoid concurrent use with:
- Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine) - significantly reduce itraconazole levels
- Drugs metabolized by CYP3A4 where elevated levels cause toxicity
Hepatotoxicity
Monitor liver function, especially in patients with pre-existing hepatic disease or those on other hepatotoxic medications 5. Strongly discourage use in patients with elevated liver enzymes unless benefit clearly outweighs risk.
Special Populations
- Renal impairment: Limited data; dose adjustment may be needed due to potentially lower exposure 5
- Hepatic impairment: Use with extreme caution; consider prolonged half-life when initiating other CYP3A4-metabolized drugs 5
- Elderly: Increased risk of hearing loss, particularly with concurrent quinidine (contraindicated) 5
Practical Algorithm
- Confirm diagnosis with mycological examination before treatment
- Identify pathogen:
- Dermatophyte → Terbinafine first-line; itraconazole second-line
- Candida → Itraconazole first-line
- Non-dermatophyte molds → Itraconazole preferred
- Choose regimen:
- Pulse therapy offers similar efficacy with potentially better compliance
- Continuous therapy achieves higher nail concentrations
- Duration: Re-evaluate 3-6 months post-treatment; expect high recurrence rates (20-30%) 6